NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

The NCP Flanders Team

Ready to go the extra mile for you. Don't be shy and contact us!

Meet our team

The NCP Flanders' team consists of 13 persons.

Feel free to reach out to them directly, or use info@ncpflanders.be when it is not clear whom to contact.

We use a simple colour code for the programme labels throughout the site: green is for Horizon Europe, blue is for Horizon 2020 and purple is for Digital Europe. Yellow is used for NCP Flanders related topics.

You can as well visit the Horizon Europe Horizon 2020, Digital Europe, or Defence pages to browse by programme domain and find the responsible NCPs there for each topic.

NCP Flanders is a cooperation between FWO, the Research Foundation Flanders, and VLAIO, Flanders Innovation & Entrepreneurship.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.